---
title: "diagnostic tests uiofire respiratory panel"
year: 2023
month: 08
journal: "American Family Physician"
volume: "108"
issue: "08"
pages: ""
doi: ""
pmid: ""
source: "PDF Extraction"
pdf_available: true
original_pdf: "2023-08-diagnostic-tests-biofire-respiratory-panel.pdf"
extracted_date: "2025-08-10"
keywords: []
evidence_level: ""
clinical_significance: ""
---

# diagnostic tests uiofire respiratory panel

                                                     Diagnostic Tests
                                                  What Physicians Need to Know

     BioFire Respiratory Panel for the Detection
               of Viruses and Bacteria
                                 Nick F. Bennett, DO, MBA, FAAFP, and Ashley L. Bissaillon, DO
                               Madigan Army Medical Center Family Medicine Residency, Tacoma, Washington




                 Test                       Indication                               Population                                     Cost*

                 BioFire Respira-           Rapidly detect common viral              Any patient with signs or symp-                $417
                 tory 2.1 Panel             and bacterial pathogens†                 toms of respiratory tract infection

                 *—Reimbursement rate according to the 2023 Centers for Medicare and Medicaid Services clinical laboratory fee
                 schedule. This price is the out-of-pocket cost to the patient.10,11
                 †—Viruses:​adenovirus, coronavirus (229E, HKU1, NL63, OC43), Middle East respiratory syndrome coronavirus, SARS-
                 CoV-2, human metapneumovirus, human rhinovirus/enterovirus, influenza A virus (A/H1, A/H3, A/H1-2009), influenza B
                 virus, parainfluenza virus (1, 2, 3, 4), respiratory syncytial virus. Bacteria:​Bordetella parapertussis, B. pertussis, Chlamydia
                 pneumoniae, Mycoplasma pneumoniae.1




            The BioFire Respiratory 2.1 Panel (RP2.1) is Benefit
            a multiplex polymerase chain reaction (PCR)                            Although the BioFire RP2.1 test allows for iden-
            test that identifies nucleic acids from 23 differ-                     tification of many common respiratory tract
            ent bacteria and viruses that commonly cause                           infections in 45 minutes, there is limited clinical
            upper and lower respiratory tract infections.                          benefit. A 2015 observational study of outpatient
            It is a point-of-care nasopharyngeal swab that                         respiratory pathogen testing used in 295 adults
            provides quick and accurate results.1 The U.S.                         was notable for a decrease in antibiotic use in
            Food and Drug Administration granted the                               those who tested positive for influenza.5 However,
            BioFire RP2.1 test emergency use authorization                         there was no difference in antibiotic use in those
            in May 2020 and marketing authorization in                             who tested positive for other viruses or negative
            March 2021, making it the first test including                         for all viruses (48.6% and 49.3%, respectively).
            SARS-CoV-2 to be marketed beyond the height                            A 2019 retrospective cohort study of 243 adults
            of the pandemic.2                                                      discharged from the emergency department and
                                                                                   243 adults who were hospitalized had similar
            Accuracy                                                               findings.6 In patients discharged from the emer-
            The BioFire RP2.1 tests for 19 viral and four bac-                     gency department, antibiotic use was lower only
            terial pathogens. Table 1 summarizes data from a                       in those who tested positive for influenza, with an
            prospective multicenter study of 1,612 respiratory                     average of 0.5 days of antibiotic therapy compared
            samples from symptomatic patients in three hos-                        with 2.7 days for those with negative test results
            pitals and another prospective multicenter study                       and 1.8 days for those negative for influenza. No
            of 524 samples.3,4                                                     statistically significant decrease in antibiotic use
                                                                                   occurred in hospitalized patients who received
                                                                                   respiratory pathogen testing. In a 2019 random-
               This series is coordinated by Natasha Pyzocha,                      ized controlled study of 800 hospitalized adults,
               DO, contributing editor.
                                                                                   adding respiratory pathogen testing to routine
               A collection of Diagnostic Tests published in
                                                                                   real-time PCR reduced the duration of intrave-
               AFP is available at https://​w ww.aafp.org/afp/
               diagnostic.                                                         nous antibiotics (seven vs. eight days;​P < .001)
               Author disclosure:​No relevant financial
                                                                                   and shortened the length of hospitalization (eight
               relationships.                                                      vs. nine days;​P < .001) compared with real-time
                                                                                   PCR testing alone.7

Downloaded
August 2023 from the American
             ◆ Volume         Family Physician
                       108, Number    2        website at www.aafp.org/afp.        © 2023 American Academy of American
                                                                            Copyright
                                                             www.aafp.org/afp                                              Family
                                                                                                               Family Physicians.     the private, 189
                                                                                                                                  ForPhysician     non-
commercial use of one individual user of the website. All other rights reserved. Contact copyrights@aafp.org for copyright questions and/or permission requests.
                                                          DIAGNOSTIC TESTS



             TABLE 1

             Accuracy Data for the BioFire RP2.1 Test Extrapolated From 2018 and 2022
             Multicenter Clinical Studies
             Pathogen                      No. detected       Sensitivity (%)      Specificity (%)      LR+              LR–

             Viruses
             Adenovirus                    118                 94.6                 96.9                  30.5           0.06
             Coronavirus HKU1               16                100                   99.2                 125.0           0.00
             Coronavirus NL63               50                100                   99.4                 166.7           0.00
             Coronavirus 229E               16                 91.7                 99.7                 305.7           0.08
             Coronavirus OC43               38                 80.5                 99.7                 268.3           0.20
             MERS-CoV                        0                 NA                  100                    NA             NA
             SARS-CoV-2                    524                 98.4                 98.9                   0.0           0.00
             Human                          81                 97.3                 99.5                 194.6           0.03
             metapneumovirus
             Human rhinovirus/             502                  97.5                93.5                   15.0          0.03
             enterovirus
             Influenza A                     78               100                  100                    NA             0.00
             Influenza A/H1                   0                NA                  100                    NA             NA
             Influenza A/H3                  4                100                  100                    NA             0.00
             Influenza A/H1-2009            74                100                  100                    NA             0.00
             Influenza B                    16                100                   99.9                1000.0           0.00
             Parainfluenza virus 1          10                100                   99.9                1000.0           0.00
             Parainfluenza virus 2          54                 97.9                 99.5                 195.8           0.02
             Parainfluenza virus 3          53                 95.6                 99.4                 159.3           0.04
             Parainfluenza virus 4          16                100                   99.6                 250.0           0.00
             Respiratory syncytial         199                 99.4                 98.3                  58.5           0.01
             virus

             Bacteria
             Bordetella pertussis             3                66.7                 99.9                 667.0           0.33
             B. parapertussis                 6                85.7                100                    NA             0.14
             Chlamydia                        6               100                   99.9                1000.0           0.00
             pneumoniae
             Mycoplasma                      28                 95.8                99.7                  319.3          0.04
             pneumoniae

             LR+ = positive likelihood ratio;​LR− = negative likelihood ratio; MERS-CoV = Middle East respiratory syndrome corona-
             virus; NA = not available.
             Information from references 3 and 4.




            In a quasi-randomized trial of 545 hospitalized              for those who underwent respiratory pathogen
          adults, no statistically significant correlation was           testing, compared with non-PCR methods.9 More
          identified between respiratory pathogen testing                than one-half (54.3%) of children whose results
          and length of hospitalization or duration of anti-             were positive for a viral pathogen on respiratory
          biotic use, but there was a decrease in time to first          pathogen testing still received antibiotics.
          dose of antivirals when using respiratory patho-
          gen testing compared with routine, laboratory-                 Harms
          based respiratory PCR and serology testing.8 In                Although the BioFire RP2.1 test includes 23 dif-
          a 2016 retrospective, case-control study of 2,430              ferent viruses and bacteria, it is not comprehen-
          children, there were decreased antibiotic use (four            sive. This testing can lead to anchoring bias, and
          vs. five median antibiotic days;​P < .01) and fewer            an initial positive result may lead to the absence
          chest radiographs ordered (59% vs. 78%;​P < .01)               of a broader differential. Positive results do not

190 American Family Physician                             www.aafp.org/afp                                Volume 108, Number 2 ◆ August 2023
                                                       DIAGNOSTIC TESTS


          rule out coinfection from other organisms not               References
          being tested.                                                1. The BioFire Respiratory 2.1 (RP2.1) Panel. Accessed Octo-
                                                                          ber 20, 2022. https://www.biofiredx.com/products/
          Cost                                                            the-filmarray-panels/filmarrayrp/
                                                                       2. U.S. Food and Drug Administration. FDA permits market-
          The BioFire RP2.1 test is authorized for use on
                                                                          ing of first SARS-CoV-2 diagnostic test using traditional
          the BioFire FilmArray 2.0 and BioFire Torch                     premarket review process. March 17, 2021. Accessed
          Systems. The reimbursement rate for the con-                    October 20, 2022. https://​w ww.fda.gov/news-events/
                                                                          press-announcements/fda -permits-marketing-first-
          sumable RP2.1 test is $417, according to the
                                                                          sars-cov-2-diagnostic-test-using-traditional-premarket-
          2022 Centers for Medicare and Medicaid Ser-                     review-process
          vices clinical laboratory fee schedule;​however,             3. Leber AL, Everhart K, Daly JA, et al. Multicenter evaluation
          respiratory panels testing for six or more patho-               of BioFire FilmArray Respiratory Panel 2 for detection of
                                                                          viruses and bacteria in nasopharyngeal swab samples.
          gens are not eligible for this reimbursement, per               J Clin Microbiol. 2018;​56(6):​e01945-e17.
          Medicare policy.10,11 This is in contrast to influ-         4. Berry GJ, Zhen W, Smith E, et al. Multicenter evaluation
          enza A and B, SARS-CoV-2, and respiratory                      of the BioFire Respiratory Panel 2.1 (RP2.1) for detection
          syncytial virus multiplex testing, which is fully              of SARS-CoV-2 in nasopharyngeal swab samples. J Clin
                                                                         Microbiol. 2022;​60(5):​e0006622.
          covered by Medicare at a reimbursement rate of
                                                                       5. Green DA, Hitoaliaj L, Kotansky B, et al. Clinical utility
          $143.12 Additionally, the capital purchase of the               of on-demand multiplex respiratory pathogen testing
          BioFire FilmArray and BioFire Torch Systems                     among adult outpatients. J Clin Microbiol. 2016;​5 4(12):​
          can cost $37,500 and $35,000, respectively (Bio-                2950-2955.
                                                                      6. Manatrey-Lancaster JJ, Bushman AM, Caligiuri ME, et al.
          Fire Diagnostics sales, personal communication,
                                                                         Impact of BioFire FilmArray respiratory panel results on
          December 29, 2022).                                            antibiotic days of therapy in different clinical settings.
                                                                         Antimicrob Steward Healthc Epidemiol. 2021;​1(1):​e 4.
          Bottom Line                                                  7. Shengchen D, Gu X, Fan G, et al. Evaluation of a molecular
                                                                          point-of-care testing for viral and atypical pathogens on
          The BioFire RP2.1 is a rapid and accurate test                  intravenous antibiotic duration in hospitalized adults with
          that can assist with timely antiviral therapy                   lower respiratory tract infection:​a randomized clinical
          and infection control measures, but evidence is                 trial. Clin Microbiol Infect. 2019;​25(11):​1415-1421.
          mixed over its clinical benefit in decreasing the           8. Andrews D, Chetty Y, Cooper BS, et al. Multiplex PCR
                                                                         point of care testing versus routine, laboratory-based
          length of antibiotic use in adults.5-9 In agreement            testing in the treatment of adults with respiratory tract
          with the Infectious Diseases Society of America                infections:​ a quasi-randomised study assessing impact
          2018 recommendations, broad respiratory patho-                 on length of stay and antimicrobial use. BMC Infect Dis.
                                                                         2017;​17(1):​671.
          gen panels should be used only when they affect
                                                                       9. Subramony A, Zachariah P, Krones A, et al. Impact of mul-
          patient management, such as to alter empiric                    tiplex polymerase chain reaction testing for respiratory
          antimicrobial therapy or to change infection                    pathogens on healthcare resource utilization for pediatric
          control measures.13 Instead of ordering large                   inpatients. J Pediatr. 2016;​173:​196-201.e2.
                                                                      10. The BioFire CodeMap. Accessed October 20, 2022.
          multiplex tests, physicians should consider using
                                                                          https://​w ww.codemap.com/biofiredx/​i ndex.cfm?​p age=​
          tests of commonly suspected pathogens based on                  respiratory
          location, season, and patient history.13 However,           11. United HealthCare. Laboratory services policy, pro-
          immuno­compromised and critically ill patients                  fessional. Accessed November 1, 2022. https://www.
                                                                          uhcprovider.com/content/dam/provider/docs/public/
          with pneumonia and exacerbations of airway                      policies/comm -reimbursement/COMM- Laborator y-
          disease may benefit from the use of the BioFire                 Services-Policy.pdf
          RP2.1 test, which is endorsed by the Infectious             12. Centers for Medicare and Medicaid Services. 22CLABQ3.
          Diseases Society of America’s 2020 diagnostic                   Item #87636. Accessed December 29, 2022. https://​w ww.
                                                                          cms.gov/medicaremedicare-fee-​service-​paymentclinicall
          committee.14                                                    abfeeschedclinical-laboratory-fee-schedule-files/22clabq3
          The opinions and assertions contained herein are the        13. Miller JM, Binnicker MJ, Campbell S, et al. A guide to uti-
          private views of the authors and are not to be con-             lization of the microbiology laboratory for diagnosis of
          strued as official or as reflecting the views of the U.S.       infectious diseases:​2018 update by the Infectious Dis-
                                                                          eases Society of America and the American Society for
          Army, the U.S. Department of Defense, or the U.S.
                                                                          Microbiology. Clin Infect Dis. 2018;​67(6):​e1-e94.
          government.
                                                                      14. Hanson KE, Azar MM, Banerjee R, et al. Molecular testing
          Address correspondence to Nick F. Bennett, DO,                  for acute respiratory tract infections:​clinical and diagnos-
          MBA, FAAFP, at nick.f.bennett.civ@​health.mil.                  tic recommendations from the IDSA’s Diagnostics Com-
          Reprints are not available from the authors.                    mittee. Clin Infect Dis. 2020;​71(10):​2744-2751. ■




August 2023 ◆ Volume 108, Number 2                      www.aafp.org/afp                                    American Family Physician 191
